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EPIDEMIOLOGY/POPULATION SCIENCE
Isolated Diastolic Hypertension in the IDACO 
Study: An Age-Stratified Analysis Using 24-Hour 
Ambulatory Blood Pressure Measurements
John W. McEvoy ,* Wen-Yi Yang ,* Lutgarde Thijs , Zhen-Yu Zhang , Jesus D. Melgarejo , José Boggia ,  
Tine W. Hansen , Kei Asayama , Takayoshi Ohkubo , Eamon Dolan, Katarzyna Stolarz-Skrzypek, Sofia Malyutina,  
Edoardo Casiglia , Lars Lind , Jan Filipovský , Gladys E. Maestre , Yan Li , Ji-Guang Wang , Yutaka Imai,  
Kalina Kawecka-Jaszcz, Edgardo Sandoya , Krzysztof Narkiewicz , Eoin O’Brien, Thomas Vanassche, Jan A. Staessen ;  
on behalf of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO)  
Investigators
ABSTRACT: The prognostic implications of isolated diastolic hypertension (IDH), as defined by 2017 American College of 
Cardiology (ACC)/American Heart Association (AHA) guidelines, have not been tested using ambulatory blood pressure (BP) 
monitor thresholds (ie, 24-hour mean systolic BP <125 mm Hg and diastolic BP ≥75 mm Hg). We analyzed data from 11 135 
participants in the IDACO (International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes). 
Using 24-hour mean ambulatory BP monitor values, we performed Cox regression testing independent associations of IDH 
with death or cardiovascular events. Analyses were conducted in the cohort overall, as well as after age stratification (<50 
years versus ≥50 years). The median age at baseline was 54.7 years and 49% were female. Over a median follow-up of 
13.8 years, 2836 participants died, and 2049 experienced a cardiovascular event. Overall, irrespective of age, IDH on 24-
hour ambulatory BP monitor defined by 2017 American College of Cardiology/American Heart Association criteria was not 
significantly associated with death (hazard ratio, 0.95 [95% CI, 0.79–1.13]) or cardiovascular events (hazard ratio, 1.14 [95% 
CI, 0.94–1.40]), compared with normotension. However, among the subgroup <50 years old, IDH was associated with excess 
risk for cardiovascular events (2.87 [95% CI, 1.72–4.80]), with evidence for effect modification based on age (P interaction 
<0.001). In conclusion, using ambulatory BP monitor data, this study suggests that IDH defined by 2017 American College of 
Cardiology/American Heart Association criteria is not a risk factor for cardiovascular disease in adults aged 50 years or older 
but is a risk factor among younger adults. Thus, age is an important consideration in the clinical management of adults with 
IDH. (Hypertension. 2021;78:1222–1231. DOI: 10.1161/HYPERTENSIONAHA.121.17766.) • Data Supplement
Key Words: blood pressure ◼ hypertension ◼ morbidity ◼ mortality ◼ risk
Ambulatory blood pressure (BP) monitor (ABPM) recordings are considered superior to office BP recordings in quantifying cardiovascular disease 
risk.1,2 This is because 24-hour ABPM provides multiple 
recordings and gives a more precise estimate of physi-
ological BP levels during normal activity than once-off 
measurements obtained in the clinic. In addition, ABPM 
recordings offer the opportunity to determine BP values 
during sleep, which have been shown to impart prog-
nostic information.3 Consequently, our understanding of 
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One such phenotype, isolated diastolic hypertension 
(IDH), is less common than combined systolic-diastolic 
hypertension or isolated systolic hypertension (ISH).4 
However, depending on the definition applied, IDH can 
be seen in ≥6% of the adult population.5 There are 2 
definitions of IDH currently in widespread use; the 2018 
European Society of Cardiology (ESC) guideline defines 
IDH as diastolic BP ≥90 mm Hg and systolic BP <140 
mm Hg,6 and the 2017 American College of Cardiology 
(ACC)/American Heart Association (AHA) guideline 
defines IDH as diastolic BP ≥80 mm Hg with a systolic 
BP <130 mm Hg (note that both of these definitions 
assume office measurement of BP).7
There have been conflicting reports on the asso-
ciation of IDH with adverse cardiovascular outcomes, 
especially using the 2017 ACC/AHA definition.4,5,8-11 
Analyses suggesting a modest association between 
the ACC/AHA definition of IDH and events have come 
from large clinical registries that comprised of routine 
clinical recordings of BP, whereas analyses finding no 
association have analyzed BP values obtained under 
more rigorous research conditions.5,11,12 In addition, one 
of the clinical registries reporting a modest association 
between the ACC/AHA definition of IDH and events 
demonstrated clear evidence for interaction on the 
basis of age, with a stronger association between IDH 
and events among young versus old participants.10 By 
contrast, the null studies reported to date using stan-
dardized BP values obtained under rigorous research 
conditions have found no interaction by age.5,11 To clar-
ify this uncertainty, we studied cardiovascular outcomes 
in the IDACO (International Database on Ambulatory 
Blood Pressure in Relation to Cardiovascular Out-
comes) cohort among participants with IDH that was 
confirmed using 24-hour ABPM, focusing primarily on 
the 2017 ACC/AHA definition. Analyses were con-
ducted in the IDACO sample overall and after stratifica-
tion based on age.
Nonstandard Abbreviations and Acronyms
ABPM ambulatory BP monitor
ACC American College of Cardiology
AHA American Heart Association
BP blood pressure
ICD International Classification of Diseases
ICD-10 ICD, Tenth Revision
ICD-8 ICD, Eighth Revision
ICD-9 ICD, Ninth Revision
IDACO  International Database on Ambulatory 
Blood Pressure in Relation to Cardiovas-
cular Outcomes
IDH isolated diastolic hypertension
ISH isolated systolic hypertension
Novelty and Significance
What Is New?
• Using 24-hour ambulatory blood pressure monitor 
recordings, we found no statistically significant asso-
ciation between isolated diastolic hypertension (IDH) 
by 2017 American College of Cardiology (ACC)/
American Heart Association (AHA) criteria and 
increased risk for outcomes in the IDACO (International 
Database on Ambulatory Blood Pressure in Relation to 
Cardiovascular Outcomes) cohort overall.
• By contrast, when the cohort was stratified by age, 
risk for cardiovascular events was higher among per-
sons younger than 50 years who had IDH by 2017 
ACC/AHA criteria; but was not increased among older 
adults with IDH.
What Is Relevant?
• Our data indicate that IDH by the 2017 ACC/AHA 
definition is not benign for adults younger than 50 
years. These 24-hour ambulatory blood pressure moni-
tor data help to settle an open question raised in prior 
registries using less rigorous recording of blood pres-
sure, which indicated that age is an important consid-
eration in the management of patients with IDH.
Summary
These 24-hour ambulatory blood pressure monitor 
data confirm prior reports that IDH by the 2017 ACC/
AHA definition is not associated with events in adults 
overall, irrespective of their age. Our IDACO data also 
confirm the known association between IDH by the 
2018 European Society of Cardiology definition and 
events. As such, the 2018 European Society of Car-
diology definition of IDH appears to be a stronger risk 
factor for cardiovascular events than the 2017 ACC/
AHA definition. The null association between the 2017 
ACC/AHA definition of IDH and events in adults over 
50 years suggests that older adults with mild IDH 
do not need treatment as long as systolic BP is con-
trolled. However, our data also indicate that the 2017 
ACC/AHA definition of IDH is not completely benign 
for adults younger than 50 years. However, because 
young adults are at low absolute risk for events, future 
studies are needed to test whether pharmacological 
treatment of IDH in younger persons is efficacious 
and cost-effective. For now, lifestyle management is 
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METHODS
The IDACO database is not publicly available; however, the 
authors declare that all supporting data are available within the 
article (and its Data Supplement).
Study Population
Previous publications describe the IDACO database in more 
detail.3,13,14 Participating population studies qualified for inclu-
sion if office and ambulatory BP measures and cardiovascular 
risk factors were available at baseline and if follow-up included 
both fatal and nonfatal outcomes. Of 13 111 people included 
in the database, we excluded 1976, either because they were 
teenagers (<18 years) without events (n=493) or because they 
had an ambulatory BP recording with fewer than 6 daytime or 3 
nighttime readings (n=1483).15 Thus, the number of individuals 
analyzed was 11 135. We did not exclude persons on antihyper-
tensive therapy in the main analysis, although we excluded them 
in a sensitivity analysis. The expanded methods section and 
Table S1 in the Data Supplement provide detailed information 
on the population sampling methods, timelines, and country of 
recruitment. All of the included studies received ethical approval 
from the responsible institutional review boards in their country 
of origin and all participants provided written informed consent.
BP Measurement
Nurses or physicians obtained the conventional office BP clini-
cal readings with standard auscultation using a mercury sphyg-
momanometer or with validated microphone or oscillometric 
automated BP measurement devices (see Expanded Methods 
in the Data Supplement). For ambulatory BP monitoring (Table 
S2), portable monitors were programmed to obtain ambulatory 
readings at 30-minute intervals throughout the whole day or at 
intervals of 15 to 30 minutes during daytime and at intervals 
ranging from 20 to 60 minutes during the nighttime.16 Daytime 
readings ranged from 10 am to 8 pm in European and South 
American countries and from 8 am to 6 pm in Asian countries. 
The corresponding nighttime intervals ranged from midnight to 
6 am in European and South American countries and from 10 
pm to 4 am in Asian countries. The Expanded Methods section in 
the Data Supplement further describes the collection of ques-
tionnaire and biochemical data.
Ascertainment of End Points
We ascertained vital status and the incidence of fatal and 
nonfatal events from the appropriate sources in each coun-
try.14 All events were prespecified and coded according to the 
International Classification of Diseases (ICD). The coprimary 
end points were total mortality and a composite cardiovascular 
event consisting of cardiovascular mortality (ICD-8 [ICD, Eighth 
Revision], 390–448; ICD-9 [ICD, Ninth Revision], 390.0–459.9; 
and ICD-10 [ICD, Tenth Revision], I00–I79 and R96), coronary 
events (death from ischemic heart disease [ICD-8, 411–412; 
ICD-9, 411 and 414; and ICD-10, I20 and I24–I25], sudden 
death [ICD-8, 427.2 and 795; ICD-9, 427.5 and 798; and ICD-
10, I46 and R96], nonfatal myocardial infarction [ICD-8 or 
ICD-9, 410 and ICD-10, I21-I22], and coronary revasculariza-
tion), stroke (ICD-8 or ICD-9, 430–434 and 436; and ICD-10, 
I60–I64 and I67–I68, not including transient ischemic attack), 
and heart failure (ICD-8, 427.0, 427.1, 427.2, 428, 429, 519.1, 
and 782.4, ICD-9, 429, and ICD-10, I50 and J81). Secondary 
outcomes included each of the individual outcomes included 
in the composite cardiovascular event end point. All outcomes 
were validated against hospital files or medical records held by 
participants’ primary care physicians or specialists. In analyses 
of composite outcomes, we only considered the first event.
Statistical Analysis
We used the Kolmogorov-Smirnov test for assessing the nor-
mality of distributions. For comparison of means and propor-
tions, we applied the large-sample Z test and Fisher exact test, 
respectively. After stratification by cohort and sex, we interpolated 
missing values of body mass index and serum cholesterol levels 
from the regression slopes on age. In participants with unknown 
status of smoking, drinking, antihypertensive treatment, diabetes, 
or unknown history of cardiovascular disease, we set the indica-
tor (dummy) variable to the cohort- and sex-specific mean of the 
codes (0, 1). Missing values were interpolated for body mass index 
(n=33), serum cholesterol level (n=806), smoking status (n=56), 
drinking status (n=805), antihypertensive treatment (n=16), dia-
betes (n=5), and history of cardiovascular disease (n=1).
Our analysis modeled 4 categorical exposures: normoten-
sion, IDH, ISH, and combined systolic-diastolic hypertension. 
Conversion of clinic BP thresholds to their respective ABPM 
equivalents was performed as recommended in 2017 ACC/
AHA7 and in 2018 ESC hypertension guidelines.17 Specifically, 
the 24-hour systolic/diastolic ABPM thresholds for a diagno-
sis of IDH were 125/75 mm Hg by AHA/ACC and 130/80 
mm Hg by ESC criteria. Similarly, the nighttime systolic/diastolic 
ABPM thresholds for a diagnosis of IDH were 110/65 mm Hg 
by 2017 AHA/ACC and 120/70 mm Hg by 2018 ESC criteria.
We compared the cumulative incidence of the primary and 
secondary outcomes by hypertension category, after adjusting 
for age and sex. In multivariable-adjusted Cox regression, we 
adjusted for cohort (random effect), sex, and baseline charac-
teristics including age, body mass index, smoking and drinking 
status, serum cholesterol level, antihypertensive drug intake, 
diabetes, and history of cardiovascular disease. We checked 
the proportional hazards assumption by the Kolmogorov-type 
supremum test. We prespecified that all Cox regression anal-
yses were conducted in the IDACO sample overall and after 
stratification on the basis of age (<50 years versus ≥50 years) 
and sex. In these stratified analyses, we tested for effect modi-
fication using multiplicative interaction terms.
Sensitivity analyses excluded individuals either on baseline 
antihypertensive medications or those with a baseline history 
of cardiovascular disease from the models. Finally, we also per-
formed sensitivity analyses of our 4 main categorical exposures 
with further adjustment for either systolic BP or for diastolic BP 
as continuous covariables at baseline.
For the statistical analysis, we used SAS software, version 
9.4. Statistical significance was a 2-tailed α of ≤0.05.
RESULTS
Characteristics of Participants
The study sample analyzed (n=11 135) included 5494 
women (49.3%) and consisted of 6929 White Europe-




Hypertension. 2021;78:1222–1231. DOI: 10.1161/HYPERTENSIONAHA.121.17766 November 2021  1225
McEvoy et al Age-Stratified Risk of Isolated Diastolic Hypertension
Americans (20.8%). The median age at baseline was 
54.7 years. Study participants included 3022 (27.3%) 
smokers, 849 (7.6%) diabetics, and 1291 (11.6%) per-
sons with a history of cardiovascular disease.
When applying the 2017 ACC/AHA hypertension 
criteria using 24-hour ambulatory BP thresholds, our 
sample comprised of 5418 (48.7%) participants with 
normal BP values, 1129 (10.1%) with BP values meet-
ing criteria for IDH, 1325 (11.9%) with BP values meet-
ing criteria for ISH, and 3263 (29.3%) with combined 
systolic-diastolic hypertension (Table 1). In comparison to 
those with normal BP values, persons with IDH by ACC/
AHA criteria were numerically more likely to be South 
American and male. Otherwise, the baseline character-
istics of normotensive participants and those with IDH 
appeared similar, as summarized in Table 1.
Primary Analyses on the Whole Study Population
Median follow-up was 13.8 years (5th–95th percentile 
interval, 2.5–25.1 years). During 153 140 person-years 
of follow-up, 2836 participants died (incidence rate of 
18.5 per 1000 person-years) and 2049 experienced 
a composite cardiovascular event (13.4 per 1000 per-
son-years), overall. When applying the 2017 ACC/AHA 
hypertension criteria, crude incidence rates (per 1000 
person-years) for death and cardiovascular events were 
12.0 and 7.8 among normotensive participants, 9.7 
and 8.4 among those with IDH, 34.1 and 26.3 among 
those with ISH, and 27.2 and 23.5 among participants 
with combined hypertension. Age and sex-standardized 
cumulative incidence curves, for both outcomes and 
among each BP category, are presented in the Figure. 
Using the 2017 ACC/AHA criteria for IDH, there was 
no statistically significant crude excess in either mortal-
ity or cardiovascular events relative to the normal BP 
category. However, IDH according to 2018 ESC criteria 
was associated with an increased cumulative incidence 
of cardiovascular events (but not death). Irrespective of 
the guideline criteria applied, both ISH and combined 
systolic-diastolic hypertension were associated with an 
excess in death and cardiovascular events.
Table 1.  Baseline Characteristics of Participants by Hypertension Categories According to 24-Hour 
Ambulatory BP Thresholds in 2017 ACC/AHA Guidelines
Characteristic Normotensive Isolated diastolic Isolated systolic
Combined  
hypertension
N (%) of participants 5418 1129 1325 3263
 European 3352 (61.9) 649 (57.5) 863 (65.1) 2065 (63.3)
 Asian 999 (18.4) 140 (12.4) 209 (15.8) 539 (16.5)
 South American 1067 (19.7) 340 (30.1) 253 (19.1) 659 (20.2)
 Women 3239 (59.8) 485 (43.0) 599 (45.2) 1171 (35.9)
 Current smoking 1430 (26.4) 331 (29.3) 317 (23.9) 944 (28.9)
 Drinking alcohol 2422 (44.7) 569 (50.4) 755 (57.0) 2069 (63.4)
 On antihypertensive treatment 671 (12.4) 152 (13.5) 407 (30.7) 1032 (31.6)
 Diabetes 293 (5.4) 37 (3.3) 170 (12.8) 349 (10.7)
 History of CVD 452 (8.3) 114 (10.1) 253 (19.1) 472 (14.5)
Mean (SD) characteristic
 Age, y 48.6 (16.0) 49.8 (12.6) 63.2 (14.6) 58.9 (12.7)
 Body mass index, kg/m2 24.5 (4.1) 26 (4.2) 26.4 (4.7) 26.8 (4.3)
 Serum total cholesterol, mmol/L 5.4 (1.1) 5.6 (1.2) 5.8 (1.2) 5.8 (1.2)
 Blood pressure, mm Hg
  Conventional systolic 120.8 (16.6) 127.0 (14.5) 145.4 (23.6) 148.3 (22.4)
  Conventional diastolic 74.0 (9.1) 82.5 (9.2) 79.7 (10.5) 88.6 (11.4)
  24-h systolic 113.0 (6.9) 119.8 (4.0) 132.8 (8.0) 138.9 (11.3)
  24-h diastolic 67.7 (4.4) 78.3 (2.9) 70.7 (3.5) 83.3 (6.4)
  Daytime systolic 119.0 (8.5) 126.0 (6.3) 138.8 (9.7) 145.1 (12.3)
  Daytime diastolic 72.8 (5.7) 83.8 (4.7) 74.9 (5.2) 88.2 (7.4)
  Nighttime systolic 102.6 (8.3) 108.4 (7.3) 121.4 (12.5) 127.1 (14.6)
  Nighttime diastolic 58.9 (5.6) 68.1 (6.0) 62.7 (5.6) 74.0 (8.7)
The 24-h systolic/diastolic BP threshold for hypertension was 125/75 mm Hg by 2017 AHA/ACC criteria. Normotension refers to 
those with both systolic/diastolic BPs lower than the cutoff values, whereas combined hypertension refers to those with both systolic/
diastolic BPs equal to or higher than the cutoff values. Isolated systolic and diastolic hypertension refers to those with only systolic 
or diastolic BP elevated. Diabetes was a fasting plasma glucose level of ≥7.0 mmol/L or use of antidiabetic agents. ACC indicates 
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In Cox regression analyses adjusted for cohort, sex, age, 
body mass index, smoking status, alcohol drinking sta-
tus, serum cholesterol levels, antihypertensive drug treat-
ment use, diabetes, and history of cardiovascular disease 
(Table 2), there was no independent association in the 
sample overall between IDH by the 2017 ACC/AHA cri-
teria and either death (hazard ratio, 0.95 [95% CI, 0.79–
1.13]) or cardiovascular events (hazard ratio, 1.14 [95% CI, 
0.94–1.40]), compared with normotension. By contrast, 
IDH by the 2018 ESC criteria was independently associ-
ated with risk for cardiovascular events (hazard ratio, 1.44 
[95% CI, 1.12–1.85]; Table 2), but not death. Consistent 
with the above-described excesses in crude events and 
cumulative incidence rates, ISH and combined hypertension 
by both sets of diagnostic criteria also demonstrated excess 
adjusted risk in the Cox models, relative to normotension.
Figure. Sex- and age-standardized cumulative incidence of total mortality and cardiovascular (CV) event by hypertensive categories.
Relative to normotension, isolated diastolic hypertension was not associated with increased risk of death or CV events when defined according 
to 2017 American Heart Association/American College of Cardiology criteria. The 24-h systolic/diastolic ambulatory blood pressure (BP) 
thresholds were 125/75 mm Hg by 2017 American Heart Association/American College of Cardiology (A and B) and 130/80 mm Hg by 
2018 European Society of Cardiology (C and D) definitions. Normotension refers to those with both systolic/diastolic BPs lower than the 
cutoff values, whereas combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the cutoff levels. Isolated 
systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. Tabulated data are the number of participants at 
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The above results were almost identical in analyses 
of the subgroup of 8873 IDACO participants who were 
not on BP medication at baseline (Table S3). Similarly, 
when modeling participants on the basis of ABPM val-
ues at night, the results were again almost identical as for 
24-hour readings, except that nocturnal IDH by the 2018 
ESC criteria was no longer associated with cardiovascu-
lar events (results for full cohort in Table 3 and for the 
subgroup not on BP medication at baseline in Table S4).
Further Sensitivity Analyses
In sensitivity analyses, we further adjusted the categorical 
BP exposures (ie, IDH, ISH, and combined hypertension) 
for either diastolic BP or systolic BP values as baseline 
continuous covariables (Table S5 and Table S6). With fur-
ther adjustment for diastolic BP as a continuous baseline 
covariable, the results from the categorical analyses were 
consistent with the main results presented in Tables 2 
and 3. By contrast, with further adjustment for systolic 
BP as a continuous baseline covariable, there was no 
longer an association between IDH by the 2018 ESC 
definition and cardiovascular events. Second, for each of 
the individual outcomes that comprised the composite 
cardiovascular event end point, we repeated all of the 
analyses described above and found that IDH according 
to 24-hour ABPM criteria (by either guideline) was also 
not associated with any of these individual outcomes 
Table 2.  Multivariable-Adjusted HR in Relation to Hypertension Categories by 24-Hour BP
Characteristic
Total mortality (n=2836) CV event (n=2049)
HR (95% CI) P value HR (95% CI) P value
2017 AHA/ACC criteria
 Normotensive (n=5418) Reference  Reference  
 Isolated diastolic (n=1129) 0.95 (0.79–1.13) 0.55 1.14 (0.94–1.40) 0.19
 Isolated systolic (n=1325) 1.16 (1.04–1.29) 0.008 1.35 (1.18–1.53) <0.001
 Combined (n=3263) 1.35 (1.23–1.48) <0.001 1.73 (1.55–1.93) <0.001
2018 ESC criteria
 Normotensive (n=7391) Reference  Reference  
 Isolated diastolic (n=574) 1.22 (0.96–1.56) 0.11 1.44 (1.12–1.85) 0.004
 Isolated systolic (n=1429) 1.36 (1.24–1.50) <0.001 1.53 (1.37–1.71) <0.001
 Combined (n=1741) 1.39 (1.26–1.53) <0.001 1.86 (1.66–2.08) <0.001
The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by 2017 AHA/ACC and 130/80 mm Hg by 2018 ESC definitions. 
Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those 
with both systolic/diastolic BPs equal to or higher than the cutoff values. Isolated systolic and diastolic hypertension refers to those 
with only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were 
adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug 
intake, history of cardiovascular disease, and diabetes. ACC indicates American College of Cardiology; AHA, American Heart Associa-
tion; BP, blood pressure; CV, cardiovascular; CVD, CV disease; ESC, European Society of Cardiology; and HR, hazard ratio.
Table 3.  Multivariable-Adjusted HR in Relation to Hypertension Categories by Nighttime BP
Characteristic
Total mortality (n=2836) CV event (n=2049)
HR (95% CI) P value HR (95% CI) P value
2017 AHA/ACC criteria
 Normotensive (n=4766) Reference  Reference  
 Isolated diastolic (n=772) 0.99 (0.81–1.21) 0.94 1.15 (0.92–1.45) 0.22
 Isolated systolic (n=1542) 1.14 (1.02–1.27) 0.025 1.35 (1.18–1.55) <0.001
 Combined (n=4055) 1.28 (1.17–1.40) <0.001 1.62 (1.45–1.80) <0.001
2018 ESC criteria
 Normotensive (n=7362) Reference  Reference  
 Isolated diastolic (n=834) 1.08 (0.91–1.28) 0.38 1.12 (0.92–1.36) 0.26
 Isolated systolic (n=979) 1.29 (1.15–1.43) <0.001 1.44 (1.36–1.64) <0.001
 Combined (n=1960) 1.43 (1.31–1.57) <0.001 1.76 (1.58–1.96) <0.001
The nighttime systolic/diastolic BP thresholds were 110/65 mm Hg by 2017 AHA/ACC and 120/70 mm Hg by 2018 ESC definitions. 
Normotension refers to those with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those 
with both systolic/diastolic BPs equal to or higher than the cutoff levels. Isolated systolic and diastolic hypertension refers to those with 
only systolic or diastolic BP elevated. HRs express the relative risk compared with the normotensive group as reference and were adjusted 
for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total cholesterol, antihypertensive drug intake, history 
of cardiovascular disease, and diabetes. ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood 
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in isolation (Tables S7 and S8). Finally, third, analyses 
among the 9844 participants without a baseline history 
of cardiovascular disease produced consistent results 
(Tables S9 and S10).
Analyses Stratified by Age and Sex
After stratification of the whole IDACO cohort into par-
ticipants younger than 50 and participants of 50 years 
or older, there was evidence for higher crude rates of 
cardiovascular events among younger persons with IDH 
using 2017 ACC/AHA criteria (3.71 per 1000 person-
years) compared with younger persons with normal BP 
(1.08 per 1000 person-years). By contrast, crude car-
diovascular event rates among those aged 50 or more 
appeared lower in the IDH subgroup versus normoten-
sion (Table S11).
In adjusted Cox models, there was a statistically sig-
nificant 3-fold increase in adjusted relative risk for car-
diovascular events among IDACO participants younger 
than 50 who had IDH on 24-hour ABPM by 2017 
ACC/AHA criteria, relative to young participants with 
normotension (Table 4). Furthermore, there was strong 
evidence of effect modification on the basis of age (P 
interaction <0.001) and IDACO participants 50 years or 
older with IDH had no excess cardiovascular risk com-
pared to normotension. There was also a suggestion of 
effect modification by age on the association between 
IDH using the 2018 ESC criteria and cardiovascular 
events; with marginal evidence for higher risk in younger 
adults than older adults (P interaction =0.06). In con-
trast to cardiovascular events, IDH on 24-hour ABPM 
(either by 2017 ACC/AHA or by 2018 ESC criteria) 
was not significantly associated with mortality at any age 
and there was no evidence of interaction on the basis 
of age (Table 4). Similarly, for both the 2018 ESC or 
2017 ACC/AHA criteria, the risks of total mortality and 
cardiovascular events associated with IDH were similar 
among men and women in the whole IDACO cohort (P 
interaction =0.10, Tables S12 and S13).
DISCUSSION
In this international study of adults with 24-hour ABPM 
recordings, 2 interesting and novel findings become evi-
dent. First, we found no association of IDH, as defined by 
the 2017 ACC/AHA guideline and using 24-hour ABPM 
readings, with adverse outcomes in the sample overall. By 
contrast and concordant with prior IDACO reports,18 IDH 
on 24-hour ABPM as defined by the 2018 ESC guide-
line was associated with cardiovascular events, although 
not with death. The second observation, which addresses 
an issue of controversy12, was that after stratifying the 
study sample by age, IDH on 24-hour ABPM was asso-
ciated with increased risk for cardiovascular events (both 
for the 2017 ACC/AHA and the 2018 ESC definitions 
of IDH) among participants younger than 50 years only.
ACC/AHA Versus ESC Definitions of IDH 
Among Adults of All Ages
The first main finding from this IDACO report is con-
sistent with prior research.5,11 By using 24-hour and 
nocturnal ABPM recordings, the current results are an 
important validation of the report by McEvoy et al,5 which 
analyzed adults of all ages participating in a number of 
US cohorts who had BP values collected at a single 
point in time as part of a research study visit. The IDACO 
Table 4.  Multivariable-Adjusted HR in Relation to Hypertension Categories After Stratification by Age
Characteristic




 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
2017 AHA/ACC criteria
 Normotensive Reference  Reference   Reference  Reference   
 Isolated diastolic 1.66 (0.96–2.86) 0.068 0.91 (0.75–1.10) 0.31 0.076 2.87 (1.72–4.80) <0.001 0.98 (0.78–1.23) 0.87 <0.001
 Isolated systolic 0.68 (0.21–2.20) 0.52 1.14 (1.03–1.28) 0.015 0.28 0.74 (0.22–2.43) 0.62 1.33 (1.17–1.52) <0.001 0.45
 Combined 2.08 (1.33–3.25) 0.0013 1.33 (1.21–1.46) <0.001 0.15 2.39 (1.47–3.89) <0.001 1.68 (1.50–1.88) <0.001 0.092
ESC 2018 criteria
 Normotensive Reference  Reference   Reference  Reference   
 Isolated diastolic 1.82 (0.93–3.57) 0.080 0.91 (0.75–1.10) 0.22 0.31 2.41 (1.30–4.45) 0.0052 1.31 (0.99–1.72) 0.058 0.058
 Isolated systolic 0.98 (0.39–2.46) 0.97 1.36 (1.24–1.49) <0.001 0.39 1.48 (0.66–3.31) 0.34 1.52 (1.35–1.70) <0.001 0.76
 Combined 2.28 (1.38–3.78) 0.0013 1.37 (1.24–1.51) <0.001 0.097 2.34 (1.38–4.00) 0.0017 1.82 (1.63–2.04) <0.001 0.24
The 24-h systolic/diastolic BP thresholds were 125/75 mm Hg by 2017 AHA/ACC and 130/80 mm Hg by 2018 ESC definitions. Normotension refers to those 
with both systolic/diastolic BPs lower than the cutoff values, while combined hypertension refers to those with both systolic/diastolic BPs equal to or higher than the 
cutoff levels. Isolated systolic and diastolic hypertension refers to those with only systolic or diastolic BP elevated. HRs express the relative risk compared with the 
normotensive group in the age stratification as reference and were adjusted for cohort (random effect), sex, age, body mass index, smoking and drinking, serum total 
cholesterol, antihypertensive drug intake, history of cardiovascular disease and diabetes. Pint is for the interaction between hypertension classifications and age group. 
ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; CV, cardiovascular; ESC, European Society of Cardiology; HR, 
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results presented here also align with findings from 
the UK Biobank.11 In all of these reports, there was no 
excess cardiovascular risk associated with IDH by the 
2017 ACC/AHA definition when all participants, irre-
spective of age, were included in analyses. An advantage 
of our IDACO data is that the use of 24-hour ABPM 
values allows for a more precise measurement of the 
IDH exposure than has previously been possible, even 
allowing for the rigorous methods used to record BP in 
the prior analyses.5,11
Therefore, these IDACO data challenge prior reports 
from four large clinical registries, which have suggested 
a modest increase in adjusted risk for IDH by the 2017 
ACC/AHA definition among adults of all ages.4,10,19,20 
These registries studied adults attending routine clinical 
care visits (thereby introducing the possibility of some 
confounding by indication) and who had routine, non-
standardized, clinical measurement, and documentation 
of BP. It is known that routine clinical measurement of 
BP and recording in electronic health records are not 
as accurate as standardized assessments undertaken as 
part of rigorous epidemiological studies like IDACO (this 
is true in particular for diastolic BP).21
This IDACO analysis also confirms data from UK Bio-
bank,11 and elsewhere,8 demonstrating an increased risk 
for events among adults of all ages with IDH as defined 
by the 2018 ESC criteria. The apparent conflict between 
the 2017 ACC/AHA and 2018 ESC definitions of IDH 
can be explained by the former definition requiring a 
diastolic BP ≥80 mm Hg, whereas the latter requires a 
diastolic BP ≥90 mm Hg. This suggests that, among all 
adults with controlled systolic BP, risk for cardiovascular 
events is low when diastolic BP is between 80 and 89 
mm Hg but increases once diastolic BP is ≥90 mm Hg.
ACC/AHA Definition of IDH and Outcomes in 
Young Versus Old Adults
The second main finding from this IDACO analysis sug-
gests that, by contrast to adults of all ages, the 2017 
ACC/AHA definition of IDH may be a specific prognos-
tically adverse feature in young adults aged <50 years. 
This question is important for several reasons. First, IDH 
is more common in younger adults,22 and about half of 
those newly eligible for a diagnosis of IDH since 2017 
ACC/AHA guidelines are aged <50 years.5 Second, the 
only prior report suggesting interaction by age in the 
association between the 2017 ACC/AHA definition 
of IDH and events comprised of routinely collected BP 
data from a large clinical registry and may have con-
sequently had methodological biases for the reasons 
outlined above.9,10 Prior reports of cohorts with rigor-
ous BP measurements that looked for age interaction 
in the association between the 2017 ACC/AHA IDH 
definition and events have suggested that young adults 
were not at increased risk, although these same cohorts 
included few younger adults and so may have been 
underpowered.11 Therefore, it has been unclear whether 
young adults have increased risk for events when IDH 
by the 2017 ACC/AHA definition is ascertained using 
research-quality BP measurements.
In IDACO, we found that younger adults with IDH 
by the 2017 ACC/AHA definition and measured using 
24-hour ABPM did indeed have increased risk for car-
diovascular events (but not death). This finding utiliz-
ing rigorous ascertainment of BP with ABPM confirms 
suggestions from prior studies (which used less valid 
routine clinical assessment of BP)9,10 that there is an 
age-related interaction in the association between the 
2017 ACC/AHA definition of IDH and events, with far 
stronger excesses in relative risk among young adults 
aged less than 50 years compared with older adults. The 
physiological reasons for this age interaction are not fully 
known; however, a few considerations are worth noting; 
(1) diastolic BP has been shown to have more prognos-
tic significance in the young versus the old18 and (2) the 
prevalence of elevated diastolic BP is as low as 10% (or 
less) among adults over 70 years,4 and, therefore, some 
cases of IDH in older IDACO adults may have been 
misclassified due to BP measurement error on both 
office and 24-hour ABPM (noting that increased vas-
cular stiffness with aging increases the likelihood of the 
fifth Korotkoff sound being absent, which could result 
in falsely elevated diastolic BP readings and, therefore, 
false positive IDH ascertainments).
Finally, several factors might help to explain why this 
IDACO age-stratified finding contrasts with the prior epi-
demiological studies using research-grade BP measure-
ments,5,11 none of which have found an age interaction 
for the 2017 ACC/AHA definition of IDH. First, the very 
large IDACO dataset is well powered to test this inter-
action effect, whereas prior studies may not have been; 
second, the IDACO sample is younger on average than 
some of the prior analyses5 testing the 2017 ACC/AHA 
definition of IDH; and, third, by using 24-hour ABPM 
readings, our IDACO data were less likely to include spu-
rious or artifactual readings of elevated diastolic BP that 
may be more commonly seen in BP assessments at a 
single point in time.
Limitations
This observational analysis has limitations. First, we can-
not exclude residual confounding, including but not lim-
ited to lipid-lowering and antiplatelet therapies. Second, 
24-hour BP and antihypertensive drug treatment status 
were only recorded at baseline and could therefore not 
be adjusted for as a time-dependent covariables. Fur-
thermore, our sensitivity analysis excluding persons on 
antihypertensives at baseline may have included some 
persons subsequently started on therapy. Third, our pre-
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heart rate; however, in further sensitivity analyses add-
ing heart rate to this model, the results remained quan-
titatively and qualitatively very similar (data not shown). 
Fourth, there might be misclassification bias in the 
assessment of the cardiovascular study end points.23 
However, all-cause mortality does not require any adju-
dication and is therefore not subject to this bias. Fifth, 
diastolic BP levels as assessed using automated oscillo-
metric ABPM devices can sometimes overestimate true 
diastolic BP as measured using intra-arterial transduc-
ers. In addition, although categorical analyses of diastolic 
BP have implications for clinical care (given the use of 
specific BP thresholds to define hypertension), it is also 
worth noting that BP is a continuous pathophysiologic 
exposure variable. Sixth, our findings of interaction by 
age could represent the play of chance; however, they 
were prespecified and the highly significant P interac-
tion values also make this less likely, as do prior data 
from registry studies suggesting significant interaction 
by age on the association between IDH (by both 2017 
ACC/AHA and by 2018 ESC criteria) and cardiovascu-
lar events.10 Finally, eighth, no Black participants were 
included in the IDACO database, and caution should be 
taken when extrapolating our results to races and eth-
nicities that were not included.
Perspectives
This prospective cohort analysis of 24-hour ambulatory 
BP data did not demonstrate an association between 
the 2017 ACC/AHA definition of IDH and outcomes in 
the IDACO sample overall. However, significant effect 
modification was noted on the basis of age and persons 
younger than 50 years with IDH as defined by the 2017 
ACC/AHA criteria for 24-hour ABPM readings did have 
evidence for increased risk of cardiovascular events. 
These data, using rigorous 24-hour ABPM assessments, 
indicate that the clinical implications of IDH differ greatly 
based on the patient’s age. Older persons (>50 years) 
with evidence of IDH appear to be a little risk as long as 
systolic BPs are controlled. However, younger persons 
with IDH do have elevated relative risk for cardiovas-
cular events and may therefore benefit from intensive 
lifestyle interventions and, where clinically appropriate, 
antihypertensive medications.
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